Use of therapeutic plasma exchange in COVID‐19: A systematic review of current evidence

Current knowledge related to employment of plasma exchange for treatment in COVID‐19 is predominantly based on casuistic evidence in the form of single‐center case‐series. Published data encompass reports from a total of approximately 225 patients. Based on published reports, therapeutic plasma exchange has generally been employed as rescue or adjunctive therapy in patients with critical illness, with proposed benefit attributed possible effects on mitigation and amelioration of cytokine storm syndrome. Treatment effects remain uncertain, with the impact of plasma exchange on critical illness in COVID inconclusive with regard to both efficacy and safety.